Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | OGT | O15294 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005732 | 0.98 | GRM5 (0.64) | GRM5EPHX2PBRM1MCL1OGT | |
| 4-Acetyl-2-Benzoxazolinone SCHEMBL3546681 | 0.84 | GRM5 (0.64) | GRM5EPHX2MCL1OGT | |
| Lithium Ion SCHEMBL1005730 | 0.83 | GRM5 (0.58) | GRM5EPHX2MCL1OGT | |
| SCHEMBL1004904 | 0.80 | GRM5 (0.60) | GRM5EPHX2 | |
| SCHEMBL465947 | 0.79 | PBRM1 (0.54) | GRM5PBRM1MCL1KEAP1TDP1 | |
| SCHEMBL1005310 | 0.79 | PSMB8 (0.57) | GRM5PBRM1KEAP1TDP1 | |
| SCHEMBL1137634 | 0.76 | PSMB8 (0.61) | GRM5EPHX2MCL1OGT | |
| SCHEMBL31434922 | 0.75 | GRM5 (0.50) | GRM5 | |
| SCHEMBL1285749 | 0.72 | EPHX2 (0.50) | GRM5EPHX2MCL1OGT | |
| SCHEMBL5077255 | 0.72 | PSMB8 (0.61) | GRM5EPHX2MCL1OGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024076155-A1 | NOVEL COMPOUND AS YEATS DOMAIN INHIBITOR | 노보렉스 주식회사 | 2024-04-11 | — | — | WO | disclosed |
| EP-3436009-B1 | NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 FOR USE IN THE TREATMENT OF MATURE BRAIN DAMAGES. | Sinntaxis AB (SE) | 2024-03-06 | — | — | EP | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3856178-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164459-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-2377850-A1 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | Pharmeste S.r.l. (IT) | 2011-10-19 | — | — | EP | disclosed |
| WO-2011120604-A1 | \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ | PHARMESTE S.R.L. (IT) | 2011-10-06 | — | — | WO | disclosed |
| US-20100173961-A1 | BENZOOXAZOL-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-7709513-B2 | Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080167355-A1 | BENZOOXAZOL-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| CN-1744899-A | Piperidine derivatives as CCR5 antagonists | SMITHKLINE BEECHAM CORP (US) | 2006-03-08 | — | — | CN | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GRM5 153/4885EPHX2 1202/4885PBRM1 2134/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | GRM5 309/4885EPHX2 472/4885PBRM1 2431/4885 |
| US-20080167355-A1 | BENZOOXAZOL-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | CEL, PNLIP, LPL | GRM5 3561/4885EPHX2 256/4885PBRM1 3148/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GRM5 153/4885EPHX2 1202/4885PBRM1 2134/4885 |
| US-20100173961-A1 | BENZOOXAZOL-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | CEL, PNLIP, LPL | GRM5 3561/4885EPHX2 256/4885PBRM1 3148/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | GRM5 313/4885EPHX2 2752/4885PBRM1 4404/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | GRM5 153/4885EPHX2 1202/4885PBRM1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.